by GlobeNewsWire | Oct 23, 2015 | Globe Newswire
NEW YORK, Oct. 23, 2015 (GLOBE NEWSWIRE) — The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Zafgen, Inc. (“Zafgen”) (Nasdaq:ZFGN) between January 12, 2015 and...
by editor | Oct 17, 2015 | Globe Newswire, News Buzz
Zafgen Announces Partial Clinical Hold Affecting Beloranib TrialsBOSTON, Oct. 16, 2015 (GLOBE NEWSWIRE) — Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and...
by editor | Oct 16, 2015 | StockGuru
This is one we have covered all week. Zafgen Inc. (NASDAQ: ZFGN) announced this week a death in their “Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome, a rare genetic disorder with a high rate of mortality linked to obesity and its...
by GlobeNewsWire | Oct 16, 2015 | Globe Newswire
BOSTON, Oct. 16, 2015 (GLOBE NEWSWIRE) — Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it received...
by editor | Oct 14, 2015 | Buzz
NEWER UPDATE HEREIf you follow Zafgen (NASDAQ: ZFGN), you likely have seen the stock lose 50% of value in a couple of days. The Company finally issued a statement today. Let’s take a look at that statement – below.First, let’s look at the Buzz in the...
